Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 2/20 | 0.33 |
| ▸ | EDNRA | P25101 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1474575 | 0.82 | KCNJ1 (0.38) | CCR4EDNRACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL19456627 | 0.78 | CCR4 (0.32) | CCR4EDNRA | |
| SCHEMBL15233567 | 0.74 | CCR4 (0.38) | CCR4EDNRA | |
| SCHEMBL1476090 | 0.73 | CCR4 (0.36) | CCR4EDNRA | |
| SCHEMBL4497174 | 0.73 | CCR4 (0.37) | CCR4EDNRACYP1A2CYP2C19 | |
| SCHEMBL31538061 | 0.73 | CCR4 (0.37) | CCR4EDNRACYP1A2CYP2C19 | |
| SCHEMBL10304973 | 0.71 | EDNRA (0.43) | CCR4EDNRA | |
| SCHEMBL91464 | 0.69 | LMNA (0.36) | CCR4EDNRA | |
| SCHEMBL20399659 | 0.69 | CCR4 (0.35) | CCR4EDNRA | |
| SCHEMBL5793716 | 0.69 | CCR4 (0.35) | CCR4EDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210238182-A1 | IMIDAZOPYRAZINONES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2021-08-05 | — | — | US | disclosed |
| WO-2018078042-A1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF IMIDAZOPYRAZINONES | H. LUNDBECK A/S (DK) | 2018-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238182-A1 | IMIDAZOPYRAZINONES AS PDE1 INHIBITORS | PDE12, PDE4A, PDE5A | CCR4 4181/4885EDNRA 2943/4885CYP1A2 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.